insights_auto
Miks on MVIR tõusnud? 5,77%?
Uurige põhjalikumaltchevron_right
MVIR:STO
Medivir AB
1,69Â SEK
arrow_upward
+5,77%(+0,092) 1 p
2. okt, 17:29:51 GMT +2 · SEK
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse MVIR põhistatistika genereerimine…
Ava
1,71Â SEK
Kõrge
1,78Â SEK
Madal
1,67Â SEK
Turu kapit.
1,06Â mld
Keskm. maht
1,88Â mln
Maht
2,72Â mln
52 näd kõrgeim
2,88Â SEK
52 näd madalaim
0,34Â SEK
Aktsiatulu
−0,37 SEK
Käibivad aktsiad
624,18Â mln
Töötajate arv
6
Ava
1,71Â SEK
Kõrge
1,78Â SEK
Madal
1,67Â SEK
Turu kapit.
1,06Â mld
Keskm. maht
1,88Â mln
Maht
2,72Â mln
52 näd kõrgeim
2,88Â SEK
52 näd madalaim
0,34Â SEK
Aktsiatulu
−0,37 SEK
Käibivad aktsiad
624,18Â mln
Töötajate arv
6
Uudised
Veebiallikatest ja uudistepartneritelt
Simply Wall Street
·
10 minuti eest
Will Product Recalls Change ICU Medical (ICUI) Stock Narrative
MarketBeat
·
11 minuti eest
Timken (NYSE:TKR) Downgraded by Wall Street Zen to Hold
Seeking Alpha
·
1 tunni eest
September's Leaders And Laggards
Yahoo Finance
·
1 tunni eest
BillionToOne (NasdaqGS:BLLN) Stock Fair Value Edges Higher As Analysts Weigh Tech And Reimbursement Risk
Profiil
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Teave üksuse Medivir AB kohta